These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35203643)

  • 1. Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox.
    Nagy A; Palmer E; Polivka L; Eszes N; Vincze K; Barczi E; Bohacs A; Tarnoki AD; Tarnoki DL; Nagy G; Kiss E; Maurovich-Horvat P; Müller V
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.
    Nagy A; Nagy T; Kolonics-Farkas AM; Eszes N; Vincze K; Barczi E; Tarnoki AD; Tarnoki DL; Nagy G; Kiss E; Maurovich-Horvat P; Bohacs A; Müller V
    Front Pharmacol; 2021; 12():778649. PubMed ID: 35002713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry.
    Nagy T; Toth NM; Palmer E; Polivka L; Csoma B; Nagy A; Eszes N; Vincze K; Bárczi E; Bohács A; Tárnoki ÁD; Tárnoki DL; Nagy G; Kiss E; Maurovich-Horvát P; Müller V
    Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Lung Function Changes and Predictors of Progressive Systemic Sclerosis-Related Interstitial Lung Disease.
    Kaenmuang P; Navasakulpong A
    Tuberc Respir Dis (Seoul); 2020 Oct; 83(4):312-320. PubMed ID: 32668825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.
    Carnevale A; Silva M; Maietti E; Milanese G; Saracco M; Parisi S; Bravi E; De Gennaro F; Arrigoni E; Bodini FC; Fusaro E; Scirè CA; Sverzellati N; Ariani A
    Clin Rheumatol; 2021 Jan; 40(1):213-219. PubMed ID: 32880053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
    Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
    Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Rev Mal Respir; 2007 Oct; 24(8):1035-46. PubMed ID: 18033190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
    Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
    Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
    Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
    Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural History of Systemic Sclerosis-Related Interstitial Lung Disease: How to Identify a Progressive Fibrosing Phenotype.
    Volkmann ER
    J Scleroderma Relat Disord; 2020 Mar; 5(2 Suppl):31-40. PubMed ID: 33693056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Worsening of esophageal dilatation is associated with increase in a high-resolution computed tomography (HRCT) score in early systemic sclerosis-associated interstitial lung disease (SSc-ILD).
    Wangkaew S; Losuriya P; Euathrongchit J
    Clin Rheumatol; 2021 Mar; 40(3):955-963. PubMed ID: 32803568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
    Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
    Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression.
    Gargani L; Bruni C; De Marchi D; Romei C; Guiducci S; Bellando-Randone S; Aquaro GD; Pepe A; Neri E; Colagrande S; Falaschi F; Moggi-Pignone A; Pingitore A; Matucci-Cerinic M
    Clin Rheumatol; 2021 May; 40(5):1903-1912. PubMed ID: 33161470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nailfold Capillaroscopic Changes as a Marker of Interstitial Lung Disease in Systemic Sclerosis: A Cross-Sectional Study in a Tertiary Care Hospital in Eastern India.
    Rudra O; Baisya S; Mallick S; Chatterjee G
    Indian Dermatol Online J; 2022; 13(2):216-220. PubMed ID: 35287403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
    Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
    Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.